Third Point Bulks Up Distressed Debt Team Ahead Of Distressed Selling [Q3 Letter]

Privacy Policy | Advertiser Disclosure

Third Point Bulks Up Distressed Debt Team Ahead Of Distressed Selling [Q3 Letter] Dan Loeb's Third Point hedge fund returned -3.2% in its flagship strategy according to its third-quarter update, a copy of which ValueWalk has been able to review. Following this performance, the fund is down - 22.7% year to date compared to -23.9% for the S&P 500 index and 25.1% for the MSCI World Index. In […] Read More Hurricane Season Is Almost Over – In New Orleans And On Wall Street For weekend reading, Gary Alexander, senior writer at Navellier & Associates, offers the following commentary: The Hurricane Season Is Coming To An End The official "hurricane season" runs six months, from June 1 to November 30, but that's like giving "participation" trophies to three underperforming months – named June, July, and November. In reality, the […] Read More Is It Time To Snack On Mondelez Stock? Mondelez is the world's #1 biscuit company and #2 chocolate maker Snacks and candies are a durable business in both economic booms and recessions The Clif Bar acquisition complements its snack bars business generating over $1 billion in total sales Shares trade at 19.7X forward earnings paying a 2.7% annual dividend yield Snack food giant […] Read More American Express Beats Earnings & Revenue Views, Raises Guidance American Express profit came in at $2.47 per share, ahead of expectations for $2.40 per share. Revenue was $13.6 billion, also beating views. The company cited growth in goods and services spending, and travel and entertainment. Travel spending came in well ahead of expectations. The company raised its full-year earnings and revenue guidance Dow component […] Read More Snap Stock Falls As User Growth Slows To Single-Digits Snap's third quarter revenue came in at $1.13 billion, compared to 1.14 billion projected. Daily Active Users (DAU) increased to 363 million. Snap continues to struggle as restructuring costs, and falling ARPU weigh on results. Snap (NYSE:SNAP) fell in after-market trading as results did not meet investor expectations. Snap's stock declined by 25%, and this […] Read More Dark Day For Talaris Therapeutics Sees The Stock Dive 44% After Trial Patient Fatality Discusses the event and how it unfolded with market commentary It was a dark day of trading on Thursday for biopharma Talaris Therapeutics Inc (NASDAQ:TALS) after management reported a fatality of a patient that was undergoing the phase 1 trial. Talaris Therapeutics' Stock Price Drops The TALS stock price dropped as low as $1.16, trading […] Read More Copyright 2022 VALUEWALK LLC, All rights reserved. You are receiving this email because you subscribed to this newsletter on valuewalk.com Unsubscribe | Manage Subscription Preferences 295 Madison Avenue 12th floor, New York, NY 10117 973-685-6523